• 12-month MACCE rate. MACCE is defined as:all cause death,cerebrovascular event(such as stroke,)documented myocardial infarction, and [ Time Frame: 1 year after enrollment ] [ Designated as safety issue: Yes ]
  
• repeat revascularization (PCI and/or CABG) [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
  

• Overall MACCE rate at 1 month post-procedure and at 6 months, 3 and 5 years post-allocation [ Time Frame: 1 month after procedure and 6 months, 3 and 5 years post allocation ] [ Designated as safety issue: Yes ]
  
• Rates of the individual components of MACCE at 1 month post-procedure and at 6 months, 1, 3 and 5 years post-allocation [ Time Frame: 1 month after procedure and 6 months, 3 and 5 years post allocation ] [ Designated as safety issue: Yes ]
  
• Freedom from MACCE and its components at 1, 3 and 5 years post-allocation [ Time Frame: 1 year and 3 and 5 years post allocation ] [ Designated as safety issue: Yes ]
  
• Quality of life at 1 month post-procedure and at 6 months, 1, 3 and 5 years post-allocation [ Time Frame: 1 month after procedure and 6 months, 1, 3 and 5 years post allocation ] [ Designated as safety issue: No ]
  
• Cost and cost-effectiveness at 1, 3 and 5 years post-allocation [ Time Frame: 1 year, 3 and 5 years post allocation ] [ Designated as safety issue: No ]
  
• The characteristics (including co-morbidity and coronary vascular lesion complexity scoring referred to as the SYNTAX score) of the following: PCI versus CABG randomized cohort, PCI registry cohort (CABG ineligible), CABG registry cohort (PCI ineligible) [ Time Frame: 5 Years ] [ Designated as safety issue: Yes ]
  

Due to the introduction of drug-eluting stents (DESs) and to improvements in therapy for both percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) patients, PCI is challenging CABG as the gold standard for treatment of three vessel (3VD) and left main (LM) coronary disease.

SYNTAX is a novel, randomized trial with nested registries comparing PCI with paclitaxel-eluting TAXUS stents to CABG for 3VD and LM patients to evaluate the best treatment for these patients with complex coronary disease.

Patients at participating centers will be evaluated by both a cardiothoracic surgeon and by an interventional cardiologist.

Those patients who are determined to be eligible for treatment by both PCI and CABG will be randomized to receive either PCI with a polymer-based paclitaxel-eluting TAXUS stent or CABG.

Patients who are determined to be unsuitable for treatment by PCI will be treated by CABG and will be entered into a CABG registry to help define the patient population in which stenting continues to be an unacceptable treatment option.

Similarly, patients who are determined to be unsuitable for treatment by CABG will be treated by PCI, using any interventional techniques or devices with or without the use of DES, and entered into a PCI registry to help define the patients for whom CABG is considered inappropriate.